442 related articles for article (PubMed ID: 20684722)
41. Discovery of rotavirus: Implications for child health.
Bishop R
J Gastroenterol Hepatol; 2009 Oct; 24 Suppl 3():S81-5. PubMed ID: 19799704
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya.
Feikin DR; Laserson KF; Ojwando J; Nyambane G; Ssempijja V; Audi A; Nyakundi D; Oyieko J; Dallas MJ; Ciarlet M; Neuzil KM; Breiman RF
Vaccine; 2012 Apr; 30 Suppl 1():A52-60. PubMed ID: 22520137
[TBL] [Abstract][Full Text] [Related]
43. Incorporation of a rotavirus vaccine into the national immunisation schedule in the United Kingdom: a review.
Nakagomi O; Iturriza-Gomara M; Nakagomi T; Cunliffe NA
Expert Opin Biol Ther; 2013 Nov; 13(11):1613-21. PubMed ID: 24088009
[TBL] [Abstract][Full Text] [Related]
44. Economic evaluations of rotavirus immunization for developing countries: a review of the literature.
Tu HA; Woerdenbag HJ; Kane S; Rozenbaum MH; Li SC; Postma MJ
Expert Rev Vaccines; 2011 Jul; 10(7):1037-51. PubMed ID: 21806398
[TBL] [Abstract][Full Text] [Related]
45. Preventing rotavirus gastroenteritis: do you have the facts?
Davidson G; Elliott EJ; Kirkwood C; Pearce R
J Paediatr Child Health; 2007; 43(7-8):564-7. PubMed ID: 17635688
[TBL] [Abstract][Full Text] [Related]
46. Rotavirus gastroenteritis in uzbekistan: implications for vaccine policy in central Asia.
Flem ET; Musabaev E; Juraev R; Kerin T; Gentsch J; Glass RI; Bresee JS
J Infect Dis; 2009 Nov; 200 Suppl 1():S154-9. PubMed ID: 19817594
[TBL] [Abstract][Full Text] [Related]
47. Rotavirus vaccine AVANT/GlaxoSmithKline.
Jones T
Curr Opin Investig Drugs; 2001 Jul; 2(7):893-5. PubMed ID: 11757786
[TBL] [Abstract][Full Text] [Related]
48. Prevention of rotavirus disease: guidelines for use of rotavirus vaccine.
American Academy of Pediatrics Committee on Infectious Diseases
Pediatrics; 2007 Jan; 119(1):171-82. PubMed ID: 17200286
[TBL] [Abstract][Full Text] [Related]
49. Rotavirus vaccines in developing countries: the potential impact, implementation challenges, and remaining questions.
Cherian T; Wang S; Mantel C
Vaccine; 2012 Apr; 30 Suppl 1():A3-6. PubMed ID: 22520133
[TBL] [Abstract][Full Text] [Related]
50. Effectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belém, Brazil.
Justino MC; Linhares AC; Lanzieri TM; Miranda Y; Mascarenhas JD; Abreu E; Guerra SF; Oliveira AS; da Silva VB; Sanchez N; Meyer N; Shafi F; Ortega-Barria E; Soriano-Gabarró M; Colindres RE
Pediatr Infect Dis J; 2011 May; 30(5):396-401. PubMed ID: 21150692
[TBL] [Abstract][Full Text] [Related]
51. Prevention of childhood rotavirus disease through the use of Rotarix and RotaTeq vaccines.
Lepage P; Vergison A
Expert Opin Biol Ther; 2007 Dec; 7(12):1881-92. PubMed ID: 18034653
[TBL] [Abstract][Full Text] [Related]
52. Distribution of rotavirus genotypes after introduction of rotavirus vaccines, Rotarix® and RotaTeq®, into the National Immunization Program of Australia.
Kirkwood CD; Boniface K; Barnes GL; Bishop RF
Pediatr Infect Dis J; 2011 Jan; 30(1 Suppl):S48-53. PubMed ID: 21183840
[TBL] [Abstract][Full Text] [Related]
53. Sustained protection from pentavalent rotavirus vaccination during the second year of life at a large, urban United States pediatric hospital.
Boom JA; Tate JE; Sahni LC; Rench MA; Quaye O; Mijatovic-Rustempasic S; Patel MM; Baker CJ; Parashar UD
Pediatr Infect Dis J; 2010 Dec; 29(12):1133-5. PubMed ID: 20634776
[TBL] [Abstract][Full Text] [Related]
54. The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales.
Atkins KE; Shim E; Carroll S; Quilici S; Galvani AP
Vaccine; 2012 Nov; 30(48):6766-76. PubMed ID: 23000223
[TBL] [Abstract][Full Text] [Related]
55. Rotavirus and the indigenous children of the Australian outback: monovalent vaccine effective in a high-burden setting.
Snelling TL; Schultz R; Graham J; Roseby R; Barnes GL; Andrews RM; Carapetis JR
Clin Infect Dis; 2009 Aug; 49(3):428-31. PubMed ID: 19566443
[TBL] [Abstract][Full Text] [Related]
56. Rotavirus vaccines.
Vesikari T
Scand J Infect Dis; 2008; 40(9):691-5. PubMed ID: 19086243
[TBL] [Abstract][Full Text] [Related]
57. Rotavirus vaccines in Belgium: policy and impact.
Braeckman T; Van Herck K; Raes M; Vergison A; Sabbe M; Van Damme P
Pediatr Infect Dis J; 2011 Jan; 30(1 Suppl):S21-4. PubMed ID: 21183836
[TBL] [Abstract][Full Text] [Related]
58. The ORVAC trial protocol: a phase IV, double-blind, randomised, placebo-controlled clinical trial of a third scheduled dose of Rotarix rotavirus vaccine in Australian Indigenous infants to improve protection against gastroenteritis.
Middleton BF; Jones MA; Waddington CS; Danchin M; McCallum C; Gallagher S; Leach AJ; Andrews R; Kirkwood C; Cunliffe N; Carapetis J; Marsh JA; Snelling T
BMJ Open; 2019 Nov; 9(11):e032549. PubMed ID: 31727664
[TBL] [Abstract][Full Text] [Related]
59. Rotavirus infection and the current status of rotavirus vaccines.
Chen SC; Tan LB; Huang LM; Chen KT
J Formos Med Assoc; 2012 Apr; 111(4):183-93. PubMed ID: 22526206
[TBL] [Abstract][Full Text] [Related]
60. RotaTeq: Progress toward developing world access.
Goveia MG; Nelson CB; Ciarlet M
J Infect Dis; 2010 Sep; 202 Suppl():S87-92. PubMed ID: 20684723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
